A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

March 2, 2017

Study Completion Date

May 26, 2017

Conditions
Hepatitis C
Interventions
DRUG

DCV

DRUG

SOF

DRUG

RBV

Trial Locations (19)

18017

Northeast Clinical Research Center, Bethlehem

21228

Digestive Disease Associates, PA, Catonsville

22042

Inova Fairfax Hospital, Falls Church

23226

Bon Secours St. Mary's Hospital of Richmond, Inc, Richmond

30060

Gastrointestinal Specialists of Georgia, PC, Marietta

60612

Ruth Rothstein Core Center, Chicago

75203

Methodist Transplant Physicians, Dallas

76012

Texas Clinical Research Institute, Arlington

78215

The Texas Liver Institute, San Antonio

90033

Keck Medical Center Of USC, Los Angeles

94143

University Of California, San Francisco, San Francisco

02905

University Gastroenterology, Providence

T2N 4Z6

Local Institution, Calgary

T6G 2P4

Local Institution, Edmonton

V6Z 2K5

Local Institution, Vancouver

V8V 3P9

Local Institution, Victoria

M5G 2C4

Local Institution, Toronto

H3T 1E2

Local Institution, Montreal

S4O 0W5

Local Institution, Regina

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02673489 - A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection | Biotech Hunter | Biotech Hunter